Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1988 Jun;94(2):437-42.
doi: 10.1111/j.1476-5381.1988.tb11545.x.

pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets

Affiliations
Review

pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets

S R O'Donnell et al. Br J Pharmacol. 1988 Jun.

Abstract

1. The relative potencies, and equilibrium dissociation constants, for nine antagonists of platelet activating factor (Paf) have been determined on rabbit platelets (in diluted platelet-rich plasma (PRP)) in experiments in which the aggregatory response to Paf was measured. 2. Log concentration-response (% maximum) curves to Paf were obtained in the absence (controls) and presence of different concentrations of each Paf antagonist drug. The antagonists shifted the Paf curves to a higher concentration range and the slopes of the Schild plots, constructed from these data, suggested that the drugs were competitive antagonists of Paf. The slopes of the Schild plots for CV-3988 and SRI 63-119 were greater than 1. 3. The pA2 values (pKB values in parentheses) were: WEB 2086 7.31 (7.63); SRI 63-119 6.95; L-652,731 6.71 (6.73); BN 52021 6.38 (6.47); SRI 63-072 6.36 (6.43); CV-3988 5.87; 48740 RP 4.97 (5.07); ketotifen 4.94 (4.95); thiazinamium 4.73 (4.76). 4. This study provides, for the first time, some functional response data for Paf antagonists (pKB values) which are in an appropriate form for use in classifying putative Paf receptors. The study also provides the comparative potencies of these Paf antagonists in inhibiting Paf-induced platelet aggregation. WEB 2086 was the most potent of the drugs examined.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Biochem Pharmacol. 1986 Dec 15;35(24):4511-8 - PubMed
    1. Br J Pharmacol. 1986 Feb;87(2):287-9 - PubMed
    1. Agents Actions. 1986 Nov;19(3-4):246-50 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1987 Feb;335(2):103-8 - PubMed
    1. Annu Rev Pharmacol Toxicol. 1987;27:237-55 - PubMed

Publication types

MeSH terms

Substances